CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.

ESMO Open · 2021 · PMC8010395 · PMID 33743330

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

showed a trendP = 0.071so close (0.05 < p ≤ 0.1)

Results With data available from three studies ( N = 12 647), the addition of CDK4/6is to adjuvant ET showed a trend for a benefit in terms of invasive disease-free survival (IDFS; HR 0.85, 95% CI 0.71-1.01; P = 0.071).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.